A third vaccination with the corona vaccine from Biontech and Pfizer shows an effectiveness of over 95 percent, according to the two companies.
Safety concerns or unknown side effects had not been observed, said the Mainz-based company and its US partner on Thursday, citing a series of studies with over 10,000 participants.
Mainz / New York - According to the information, the dose administered was just as high as the first two vaccinations.
The study was carried out during a period in which Delta was the predominant virus variant, explained Biontech and Pfizer.
All study participants had been vaccinated twice with the Pfizer Biontech vaccine prior to the start of the study.
Their average age was 53 years.
There was an average of eleven months between the second vaccination and the booster.
also read
EMA recommends booster vaccination if the immune system is weak
For people with a weak immune system, a third vaccination is advisable after just 28 days, explains the European Medicines Agency.
The ability to form antibodies is thus improved.
EMA recommends booster vaccination if the immune system is weak
Corona third-party vaccination: How does the body react?
What are the side effects of third-party corona vaccinations?
A study from the USA offers answers.
Corona third-party vaccination: How does the body react?
Largest vaccine manufacturer wants to export vaccines again
In the face of a violent second wave in India in April and May, the Indian government had imposed an export ban on corona vaccines.
Now the deliveries are to be resumed.
Largest vaccine manufacturer wants to export vaccines again
During the study period, there were reportedly five Covid-19 cases in the booster group, while 109 cases occurred in the placebo group.
It has been shown that a booster restores the high level of vaccination protection that was achieved after the second dose, the companies said.
"These important data expand the existing knowledge and show that booster vaccinations can help to protect large parts of the population from this virus and its variants," said Biontech boss Ugur Sahin.
dpa